Wedbush Released “Outperform” Rating on TESARO Inc (TSRO)

TESARO Inc (TSRO) was Reiterated by Wedbush to “Outperform” while Lowering the Price Target of the company shares to $ 164 from a previous price target of $200 . Wedbush advised their Clients and Investors in a research report released on Mar 15, 2017.

Based on several research reports , Shares were Reiterated by Wedbush on Mar 15, 2017 to “Outperform” and Lowered the Price Target to $ 164 from a previous price target of $200 .Company shares were Downgraded by Robert W. Baird on Feb 27, 2017 to ” Neutral”, Firm has raised the Price Target to $ 182 from a previous price target of $127 .Company shares were Reiterated by RBC Capital Mkts on Feb 17, 2017 to “Outperform”, Firm has raised the Price Target to $ 202 from a previous price target of $142 .Company shares were Downgraded by FBR & Co. on Feb 16, 2017 to ” Mkt Perform”, Firm has raised the Price Target to $ 202 from a previous price target of $151 .TESARO Inc was Downgraded by Leerink Partners to ” Mkt Perform” on Feb 10, 2017.

Several company insiders have filed Insider transactions , on Mar 8, 2017, Edward C English (V.P. of Finance & Admin.) sold 10,000 shares at $178.06 per share price. According to the SEC, on Mar 3, 2017, Timothy R Pearson (Exec. VP, CFO) sold 1,447 shares at $177.61 per share price. On Mar 3, 2017, Orlando Oliveira (SVP & GM, International) sold 249 shares at $177.61 per share price, according to the Form-4 filing with the securities and exchange commission.

On the company’s financial health, TESARO Inc reported $-2.60 EPS for the quarter, missing the analyst consensus estimate by $ -0.71 based on the information available during the earnings call on Feb 28, 2017. Analyst had a consensus of $-1.89. The company had revenue of $4.20 million for the quarter, compared to analysts expectations of $4.69 million. The company’s revenue was up 1726.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.89 EPS.

TESARO Inc closed down -0.9 points or -0.59% at $152.75 with 29,74,442 shares getting traded on Wednesday. Post opening the session at $148.88, the shares hit an intraday low of $145.0001 and an intraday high of $155.89 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.


Leave a Reply

Your email address will not be published. Required fields are marked *